How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers
Türk M., Carneiro-Leão L., Kolkhir P. V., Bonnekoh H., Buttgereit T., Maurer M.
Journal of Allergy and Clinical Immunology: In Practice
Vol.8, Issue1, P. 113-124
Опубликовано: 2020
Тип ресурса: Статья
DOI:10.1016/j.jaip.2019.07.021
Аннотация:
Omalizumab is an effective treatment for patients with chronic spontaneous urticaria (CSU). In routine clinical practice, physicians often face complex cases of CSU and need to decide whether patients are suitable for omalizumab treatment and how to manage this therapy. Here, we provide evidence and experience-based answers to the most common and important questions on omalizumab treatment of CSU. At 4 large urticaria centers, questions on the use of omalizumab in the treatment of patients with CSU were collected and then ranked by frequency and importance and grouped into top 5 domains using an interactive consensus approach. We suggest that omalizumab can be used to treat patients with CSU with any of the 3 CSU phenotypes (wheals only, angioedema only, wheals and angioedema), with comorbid chronic inducible urticaria, with cancer, who receive other biologics or cyclosporine, or who are pregnant or want to become pregnant, or are breast-feeding. Omalizumab treatment should be started
Ключевые слова:
Angioedema; Chronic spontaneous urticaria; Disease response; Omalizumab; Treatment; Wheals
antihistaminic agent; biological product; corticosteroid; cyclosporine; omalizumab; placebo; add on therapy; anaphylaxis; angioneurotic edema; Article; breast feeding; chronic urticaria; clinical decision making; comorbidity; consensus development; dose response; drug dose comparison; drug efficacy; drug safety; drug use; drug withdrawal; human; hypertension; malignant neoplasm; patient-reported outcome; pelvis abscess; peritoneal and retroperitoneal infections; practice guideline; pregnancy; recurrence risk; remission; thrombocytopenia; treatment duration; urticaria
Язык текста: Английский
ISSN: 2213-2201
Türk M.
Carneiro-Leão L.
Kolkhir P. V. Pavel Vladimirovich 1982-
Bonnekoh H.
Buttgereit T.
Maurer M.
Тüрк М.
Cарнеиро-Леãо Л.
Колхир П. В. Павел Владимирович 1982-
Боннекох Х.
Буттгереит Т.
Маурер М.
How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers
Текст визуальный непосредственный
Journal of Allergy and Clinical Immunology: In Practice
Vol.8, Issue1 P. 113-124
2020
Статья
Angioedema Chronic spontaneous urticaria Disease response Omalizumab Treatment Wheals
antihistaminic agent biological product corticosteroid cyclosporine omalizumab placebo add on therapy anaphylaxis angioneurotic edema Article breast feeding chronic urticaria clinical decision making comorbidity consensus development dose response drug dose comparison drug efficacy drug safety drug use drug withdrawal human hypertension malignant neoplasm patient-reported outcome pelvis abscess peritoneal and retroperitoneal infections practice guideline pregnancy recurrence risk remission thrombocytopenia treatment duration urticaria
Omalizumab is an effective treatment for patients with chronic spontaneous urticaria (CSU). In routine clinical practice, physicians often face complex cases of CSU and need to decide whether patients are suitable for omalizumab treatment and how to manage this therapy. Here, we provide evidence and experience-based answers to the most common and important questions on omalizumab treatment of CSU. At 4 large urticaria centers, questions on the use of omalizumab in the treatment of patients with CSU were collected and then ranked by frequency and importance and grouped into top 5 domains using an interactive consensus approach. We suggest that omalizumab can be used to treat patients with CSU with any of the 3 CSU phenotypes (wheals only, angioedema only, wheals and angioedema), with comorbid chronic inducible urticaria, with cancer, who receive other biologics or cyclosporine, or who are pregnant or want to become pregnant, or are breast-feeding. Omalizumab treatment should be started